With Back-To-Back FDA Holds, Solid Hopes To Regain Footing For Duchenne Candidate

The US FDA wants more information on the first patient given SGT-001, who was hospitalized with a reduced platelet count after dosing. Solid says the patient is doing well and hopes to reply to the FDA's concerns within weeks.